Two senior doctors who co-founded Singapore's Fullerton Healthcare Corporation have been penalised for orchestrating a sophisticated expense falsification scheme spanning multiple years and jurisdictions. Daniel Chan Pai Sheng and Michael Tan Kim Song, both aged 52, received combined fines of S$160,000 on Friday for their roles in inflating entertainment claims that exceeded S$211,000 in fraudulent amounts. The case represents a significant corporate governance failure at a substantial healthcare investment company, with particular relevance to Malaysian and regional business executives operating across Southeast Asian subsidiaries.
Chan received the heavier penalty of S$135,000 after entering guilty pleas to five counts of falsifying accounts. The scope of his dishonesty was substantial: claims he submitted totalled over S$336,000, yet actual expenses amounted to merely S$125,000, meaning the inflated portion exceeded S$211,000. His co-founder Tan faced a separate S$25,000 fine after admitting guilt to a single falsification count. That particular instance involved a claimed expense of approximately S$82,000 against genuine costs exceeding S$42,000, producing an inflation of nearly S$40,000. Tan's charge formed part of the broader conspiracy involving Chan's multiple violations, indicating an organised pattern rather than isolated administrative errors.
Crucially, neither man enriched themselves through these arrangements. Court documents reveal the inflated funds were channelled specifically to support Collin Chiew, a 58-year-old former chief executive of insurance broker Aon Singapore who served in that capacity between January 2015 and July 2018. Chiew allegedly approached Chan in 2015 requesting financial assistance for personal needs including his children's education and residential expenses. Following this conversation, Chan enlisted Tan's cooperation, and together they constructed a system to generate falsified documentation and route corporate funds to their acquaintance. The scheme's architecture suggests calculated premeditation rather than spontaneous wrongdoing, with another co-founder and external facilitators integrated into the operation.
The method employed reveals how individuals within trusted financial positions can exploit corporate processes across international operations. Beginning around 2015, Chan commenced regular business trips to Hong Kong approximately twice monthly to develop FHC's presence there. Before each journey, he would request inflated or entirely fabricated karaoke establishment receipts from David Sin, the third co-founder, who arranged their preparation through Tei Chu Pink, a 46-year-old accomplice. During Hong Kong visits, Chan would socialise at KTV venues purportedly to cultivate investment relationships, yet frequently failed to make corresponding cash payments or would pay substantially reduced amounts personally. Upon returning to Singapore, Chan distributed these falsified receipts to relevant FHC personnel and Fullerton Health China staff, who processed them as legitimate business expenses, unlocking corporate funds ultimately directed to Chiew.
The operation's sophistication extended to deliberate obscuring of actual financial flows. In certain instances, Chan made minimal personal payments at entertainment venues using his own resources or personal credit facilities, creating misleading paper trails suggesting legitimate corporate entertainment. Other occasions involved no payments whatsoever, with the receipts existing purely as fraudulent documentation. The prosecutors' court papers noted that "a number of these claims were made with Tan's knowledge," indicating his active complicity rather than passive oversight. The authorities documented specific instances, including a 2016 episode where Tan, Chan and Sin collectively conspired to construct a false entertainment claim, demonstrating shared criminal intent across the leadership trio.
The judicial response included an unusual prosecutorial decision that carries implications for future cases. Authorities had initially pursued multiple corruption-related offences against both men but subsequently applied for a discharge not amounting to acquittal on all graft charges, exercising what prosecutors termed "prosecutorial discretion." Judge Paul Quan approved this application on Friday. While such discharges permit future prosecution should additional evidence emerge, the decision reflects prosecutorial assessment that falsification charges provided adequate accountability without pursuing the more serious corruption allegations. This approach may interest Malaysian legal observers considering how white-collar enforcement priorities balance multiple available charges.
Context surrounding the Fullerton Healthcare group demonstrates how the scheme operated within a substantial corporate structure. The organisation engaged in healthcare investment holdings, with subsidiary Fullerton Healthcare Group providing direct medical services through affiliated doctors and specialists while assisting clients with insurance claim processing. Tan directed operations at the group level while Chan presided over Fullerton Health China operations, positions both have since relinquished. The fraudulent system leveraged their senior positions to manipulate approval processes across multiple legal entities, suggesting weaknesses in corporate oversight mechanisms that permitted such systematic dishonesty at executive levels.
A parallel case involving David Sin, the third co-founder, underscores the systematic nature of the problem within the organisation. Sin pleaded guilty in August 2025 to six falsification counts and received an identical S$160,000 fine, suggesting comparable culpability despite differences in charge quantities. Sin's involvement in preparing fraudulent documentation and his participation in the 2016 conspiracy case indicates the misconduct pervaded the entire senior leadership rather than originating from isolated individuals. The convergence of penalties suggests courts viewed all three co-founders as substantially responsible, though they faced varying charge distributions reflecting their distinct operational roles.
For Malaysian and broader Southeast Asian readers, this case illustrates vulnerabilities in corporate governance structures when senior executives operate across multiple jurisdictions with subsidiaries in different countries. The Hong Kong-Singapore nexus enabled perpetrators to exploit approval processes and distance decision-making from scrutiny. Executives at regional companies with distributed operations across Singapore, Hong Kong, China and Southeast Asia should recognise how similar structures might facilitate financial misconduct if adequate segregation of duties, independent auditing and whistleblower mechanisms remain underdeveloped. The case demonstrates that sophisticated professionals with medical credentials and established reputations can orchestrate substantial frauds, challenging assumptions that expertise and professional standing provide sufficient ethical safeguards.
The resolution raises questions about whether S$160,000 penalties adequately deter future executive misconduct given the S$211,000 involved. Perpetrators retained their professional qualifications, faced relatively modest financial penalties compared to the fraud scale, and the principal beneficiary's prosecution remains pending with unclear outcomes regarding restitution. These factors may influence whether similar schemes appear attractive to other executives confronting financial pressures or personal obligations. Malaysian regulators and corporate boards might examine whether Singapore's response establishes sufficient deterrence, particularly concerning cases where senior figures engage in deliberate, organised fraud spanning multiple years and jurisdictions.
